Almac Group Expands Asia Pacific Presence
Almac Group announced the successful completion of the Health Sciences Authority (HSA) inspection of its new Asia Pacific headquarters in Singapore.
Almac Group announced the successful completion of the Health Sciences Authority (HSA) inspection of its new Asia Pacific headquarters in Singapore. The new facility expands on Almac's suite of clinical trial primary and secondary packaging, distribution, technology and consultation solutions offered from within the region. According to Almac’s president and managing director of Almac’s Clinical Services business unit noted 23% of global clinical trials are being conducted in Asia Pacific.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
